

IN THE CLAIMS

1. Claims 1 - 14 (Cancelled)

15. (New) A pharmaceutical composition comprising a glycosaminoglycan or salt thereof and at least one nonsteroidal anti-inflammatory drug or salt thereof optionally with pharmaceutically acceptable excipients, wherein the composition provides a gastrosparring effect and minimizes the gastric toxicity induced by the administration of nonsteroidal anti-inflammatory drug.

16. (New) The composition according to claim 15, wherein the glycosaminoglycan is Chondroitin sulphate.

17. (New) The composition according to claim 15, wherein the nonsteroidal anti-inflammatory drug is selected from the group consisting of Indomethacin, flurbiprofen, naproxen, diclofenac, ketorolac, mefenamic acid, ibuprofen, ketoprofen, meloxicam, piroxicam, nimesulide, celecoxib, rofecoxib, etoricoxib, parecoxib, valdecoxib, lumiracoxib, and salts thereof.

18. (New) The composition according to claim 16, wherein the nonsteroidal anti-inflammatory drug is selected from the group consisting of Indomethacin, flurbiprofen, naproxen, diclofenac, ketorolac, mefenamic acid, ibuprofen, ketoprofen, meloxicam, piroxicam, nimesulide, celecoxib, rofecoxib, etoricoxib, parecoxib, valdecoxib, lumiracoxib, and salts thereof.

19. (New) The composition according to claim 15, wherein the ratio of glycosamino-

glycan or salt thereof and nonsteroidal anti-inflammatory drug or salt thereof is from 100:1 to 1:100.

20. (New) The composition according to claim 15, wherein the pharmaceutically acceptable excipients are selected from the group consisting of diluents, disintegrants, fillers, bulking agents, vehicles, pH adjusting agents, stabilizers, anti-oxidants, binders, buffers, lubricants, antiadherants, coating agents, preservatives, emulsifiers, suspending agents, release controlling agents, polymers, colorants, flavoring agents, plasticizers, solvents, preservatives, glidants, and chelating agents; or a mixture thereof.

21. (New) The composition according to claim 16, wherein the pharmaceutically acceptable excipients are selected from the group consisting of diluents, disintegrants, fillers, bulking agents, vehicles, pH adjusting agents, stabilizers, anti-oxidants, binders, buffers, lubricants, antiadherants, coating agents, preservatives, emulsifiers, suspending agents, release controlling agents, polymers, colorants, flavoring agents, plasticizers, solvents, preservatives, glidants, and chelating agents; or a mixture thereof.

22. (New) The composition according to claim 1, which is formulated as an oral; pulmonary, nasal; topical; parenteral; controlled release; fast melt lyophilized; delayed release; sustained release; extended release; pulsatile release; mixed immediate release, or controlled release dosage form.

23. (New) The composition according to claim 22, wherein the oral dosage form is selected from the group consisting of tablets, pills, capsules, gels, finely divided powders, dispersions, suspensions, solutions, and emulsions.

24. (New) The composition according to claim 22, wherein the pulmonary or nasal dosage form is a spray or aerosol.
25. (New) The composition according to claim 22, wherein the topical dosage form is selected from the group consisting of gels, ointments and creams.
26. (New) A process for preparing a pharmaceutical composition according to claim 1, which comprises mixing glycosaminoglycan or salt thereof and at least one nonsteroidal anti-inflammatory drug or salt thereof, optionally with pharmaceutically acceptable excipients and formulating into a dosage form.
27. (New) The process according to claim 26, wherein the glycosaminoglycan is Chondroitin sulphate.
28. (New) A method of providing a gastrosparring effect and minimizing the gastric toxicity induced by the administration of nonsteroidal anti-inflammatory drug by administering a pharmaceutical composition comprising glycosaminoglycan or salt thereof and at least one nonsteroidal anti-inflammatory drug or salt thereof optionally with pharmaceutically acceptable excipients.